Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) Gross Margin (2016 - 2025)

China Pharma Holdings filings provide 16 years of Gross Margin readings, the most recent being 12.3% for Q4 2025.

  • On a quarterly basis, Gross Margin rose 2646.0% to 12.3% in Q4 2025 year-over-year; TTM through Dec 2025 was 3.18%, a 4066.0% increase, with the full-year FY2025 number at 3.18%, up 4066.0% from a year prior.
  • Gross Margin hit 12.3% in Q4 2025 for China Pharma Holdings, up from 7.89% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 12.3% in Q4 2025 to a low of 109.78% in Q2 2024.
  • Median Gross Margin over the past 5 years was 9.52% (2022), compared with a mean of 12.48%.
  • Biggest five-year swings in Gross Margin: tumbled -9642bps in 2024 and later surged 10130bps in 2025.
  • China Pharma Holdings' Gross Margin stood at 10.45% in 2021, then tumbled by -86bps to 1.46% in 2022, then tumbled by -352bps to 3.68% in 2023, then tumbled by -285bps to 14.16% in 2024, then skyrocketed by 187bps to 12.3% in 2025.
  • The last three reported values for Gross Margin were 12.3% (Q4 2025), 7.89% (Q3 2025), and 8.48% (Q2 2025) per Business Quant data.